Gavin MacBeath - 15 Jul 2021 Form 3 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Scientific Officer
Signature
/s/ Gavin MacBeath
Issuer symbol
TCRX
Transactions as of
15 Jul 2021
Transactions value $
$0
Form type
3
Filing time
15 Jul 2021, 18:16:17
Next filing
22 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TCRX Voting Common Stock 44.8K 15 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCRX Employee Stock Option (right to buy) 15 Jul 2021 Voting Common Stock 35.3K $1.97 Direct F1
holding TCRX Employee Stock Option (right to buy) 15 Jul 2021 Voting Common Stock 52.6K $2.46 Direct F2
holding TCRX Employee Stock Option (right to buy) 15 Jul 2021 Voting Common Stock 167K $5.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares originally subject to this option vested over 4 years of service following December 3, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement).
F2 The shares originally subject to this option vested over 4 years of service following December 5, 2019, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
F3 The shares subject to this option vest over 4 years of service following January 25, 2021, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.